Based at the Saw Swee Hock School of Public Health, National University of Singapore, ADVANCE-ID is Singapore’s 13th World Health Organisation (WHO) collaborating centre and joins a global network of institutions designated to support WHO's mandate.
ADVANCE-ID will support WHO’s global health programmes and strategic priorities with a specific focus on advancing high quality, ethically sound, clinical research with a focus on clinical trials, strengthening clinical trial ecosystems and fostering partnerships across countries.
The designation for ADVANCE-ID comes at a time when countries are increasingly recognising the importance of strong clinical research systems, including for clinical trials, in responding to public health emergencies, emerging infectious diseases and other health challenges.
In its work with WHO, ADVANCE-ID will contribute to building strong and needs based clinical trial ecosystems globally and particularly in the Western Pacific Region - promoting high quality, ethically sound trials. This includes ensuring strong trial design and standards, accelerating the generation of scientific evidence, supporting ethical inclusion of underrepresented groups, and promoting collaboration including public engagement.
Through its work, ADVANCE-ID is expected to support countries in developing stronger clinical research environments that can respond more effectively to current and future health threats.
The work of ADVANCE-ID aligns with the World Health Assembly 2022 resolution WHA75.8, which highlights the important role of clinical trials in improving access to safe and effective medical products and calls for greater equity in clinical trial capacity, participation and benefits across countries. It will support the implementation of the WHO Guidance for best practices for clinical trials and global action plan for clinical trial ecosystem strengthening.
